Innate repair receptor
Experimental research links the peptide with a receptor complex associated with tissue protection and recovery signaling.
P—20 • Investigational research profile
ARA-290
A concise educational overview of a nonerythropoietic erythropoietin-derived peptide studied in tissue-protection, inflammatory-response, and neuropathy research.
Name
ARA-290
Also known as cibenetide or pyroglutamate helix B surface peptide
- Scientific classification
- Synthetic 11-amino-acid peptide engineered from the tissue-protective region of erythropoietin
- Library family
- Regenerative
- Research status
- Investigational; supported by preclinical studies and limited early-phase human trials
- Regulatory status
- Not FDA approved
Compound overview
An erythropoietin-derived peptide designed to study tissue-protective signaling without stimulating red-blood-cell production.
ARA-290 was engineered from a region of erythropoietin associated with tissue-protective signaling rather than its blood-cell-forming activity.
Research has focused on inflammatory injury, small-fiber neuropathy, metabolic dysfunction, and repair signaling. Early trials are hypothesis-generating and do not establish broad clinical benefit.
Mechanism under study
Innate repair receptor signaling
ARA-290 is proposed to activate a tissue-protective receptor complex associated with injury response while producing little conventional erythropoietic activity.
Inflammatory regulation
Preclinical models examine modulation of inflammatory cascades following tissue stress or injury.
Neural repair research
Early human studies have evaluated neuropathic symptoms and corneal nerve-fiber measures in selected populations.
The proposed receptor biology and clinical relevance remain under investigation, and early outcomes require larger confirmatory trials.
Current research areas
Questions under investigation
- Small-fiber and diabetic neuropathy
- Inflammatory tissue injury
- Corneal nerve-fiber regeneration
- Metabolic signaling
- Long-term safety and confirmatory trials
Evidence summary
Early investigational findings
- Neuropathy research: A small Phase 2 study reported improvements in selected neuropathic-symptom measures.
- Corneal nerve research: Exploratory analyses examined changes in corneal nerve-fiber density.
- Metabolic measures: Early research reported changes in selected glucose and lipid markers.
- Tissue protection: Preclinical models support continued investigation of injury-response pathways.
The available human evidence is limited, short-duration, and insufficient to establish routine clinical effectiveness or long-term safety.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, dosing information, or instructions for ARA-290 use. ARA-290 is investigational and not FDA approved.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.